At the same time, the small amounts produced in the digestive tract and released through burping are not harmful to health for most people, even GLP-1 users who experience it more
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
But they also hope the members can use the medications as a starting point toward making the lifestyle changes necessary to maintain their weight loss
Just refer us ONE new client and AFTER your referral makes an appointment and is approved for our program, we will issue you a $50 credit on your next visit or prescription
13 GLP1-RAs have shown potential to reduce glycaemic variability while posing a low risk of hypoglycaemia
